TQB3909
As of the edition of 20 October 2026, TQB3909 is a drug known only by a code name: in active development; acts on BCL2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 8, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of TQB3909.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| BCL2 | Apoptosis regulator Bcl-2 | P10415 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 0 | 0 |
| Phase 2 | 4 | 0 | 0 | 2 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2022 to now |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | Lead sponsor of trials | 2023 to now |